Abstract:Inactivation of p53 is present in almost every tumor, and hence, p53-reactivation strategies are an important aspect of cancer therapy. Common mechanisms for p53 loss in cancer include expression of p53-negative regulators such as MDM2, which mediate the degradation of wildtype p53 (p53 alpha), and inactivating mutations in the TP53 gene. Currently, approaches to overcome p53 deficiency in these cancers are limited. Here, using non-small cell lung cancer and glioblastoma multiforme cell line models, we show that two alternatively spliced, functional truncated isoforms of p53 (p53 beta and p53 gamma , comprising exons 1 to 9 beta or 9 gamma , respectively) and that lack the C-terminal MDM2-binding domain have markedly reduced susceptibility to MDM2-mediated degradation but are highly susceptible to nonsense-mediated decay (NMD), a regulator of aberrant mRNA stability. In cancer cells harboring MDM2 overexpression or TP53 mutations downstream of exon 9, NMD inhibition markedly upregulates p53 beta and p53 gamma and restores activation of the p53 pathway. Consistent with p53 pathway activation, NMD inhibition induces tumor suppressive activities such as apoptosis, reduced cell viability, and enhanced tumor radiosensitivity, in a relatively p53-dependent manner. In addition, NMD inhibition also inhibits tumor growth in a MDM2-overexpressing xenograft tumor model. These results identify NMD inhibition as a novel therapeutic strategy for restoration of p53 function in p53-deficient tumors bearing MDM2 over expression or p53 mutations downstream of exon 9, subgroups that comprise approximately 6% of all cancers.

REGgamma modulates p53 activity by regulating its cellular localization.

REGγ modulates p53 activity by regulating its cellular localization

Differential Regulation Of The Reg Gamma-Proteasome Pathway By P53/Tgf-Beta Signalling And Mutant P53 In Cancer Cells

Differential Regulation of the REGγ–proteasome Pathway by P53/tgf-Β Signalling and Mutant P53 in Cancer Cells

Regulation Of Reg Gamma Cellular Distribution And Function By Sumo Modification

REGγ Mediated Regulation of p21 Waf/Cip1 , p16 INK4a and p14 ARF /p19 ARF in Vivo

REGγ Mediated Regulation of P21waf/cip1, P16ink4a and P14arf/p19arf in Vivo

REGgamma, a proteasome activator and beyond?

Inhibition of nonsense-mediated decay rescues p53/ isoform expression and activates the p53 pathway in and select-mutant cancers

Inhibition of Nonsense-Mediated Decay Rescues P53β/γ Isoform Expression and Activates the P53 Pathway in MDM2-overexpressing and Select P53-Mutant Cancers

Regulation of c-Myc protein stability by proteasome activator REG γ

REGγ, a proteasome activator and beyond?

Regulation of REGγ cellular distribution and function by SUMO modification

REGγ Deficiency Promotes Premature Aging Via the Casein Kinase 1 Pathway.

Site-Specific Acetylation Of The Proteasome Activator Reg Gamma Directs Its Heptameric Structure And Functions

REGγ Regulates ERα Degradation Via Ubiquitin–proteasome Pathway in Breast Cancer

The REGγ-Proteasome Regulates Spermatogenesis Partially by P53-PLZF Signaling

REGγ Accelerates Melanoma Formation by Regulating Wnt/β‐catenin Signalling Pathway

Regulation of P53 Stability As a Therapeutic Strategy for Cancer.

RB Regulates the Stability and the Apoptotic Function of P53 Via MDM2

REGγ is Critical for Skin Carcinogenesis by Modulating the Wnt/β-catenin Pathway